chloroquine

chloroquine
Name	Chloroquine
Tradename	Aralen, Resochin
Routes of administration	Oral, parenteral
Legal status	Prescription-only
Bioavailability	70–80%
Metabolism	Hepatic
Elimination half-life	1–2 months (terminal)
Excretion	Renal

chloroquine is a 4-aminoquinoline compound used historically as an antimalarial and as an immunomodulatory agent. It has been deployed in World War II-era and postwar public health campaigns against Plasmodium falciparum and Plasmodium vivax and later repurposed for rheumatologic indications such as systemic lupus erythematosus and rheumatoid arthritis. The drug’s global role has intersected with programs by World Health Organization, controversies in drug repurposing debates, and large-scale surveillance by national public health agencies including the Centers for Disease Control and Prevention.

Medical uses

Chloroquine was primarily indicated for treatment and prophylaxis of malaria caused by Plasmodium falciparum in chloroquine-sensitive regions and Plasmodium vivax where resistance is uncommon, and it was included in formularies of ministries such as the Ministry of Health of numerous countries. It has licensed uses in chronic autoimmune conditions like systemic lupus erythematosus and rheumatoid arthritis as an alternative to drugs overseen by agencies such as the U.S. Food and Drug Administration and the European Medicines Agency. In obstetric settings, chloroquine was considered for malaria prophylaxis in travelers under guidance from institutions like Royal College of Obstetricians and Gynaecologists. Off-label and emergency use proposals in outbreaks have prompted advisories from the World Health Organization and national regulators.

Mechanism of action

Chloroquine’s antimalarial activity derives from accumulation within the acidic digestive vacuole of Plasmodium falciparum parasites, where it interferes with heme detoxification pathways that were characterized in biochemical studies at institutions like the Pasteur Institute and Rockefeller University. The drug prevents biocrystallization of haematin into hemozoin, increasing intravacuolar toxicity and causing parasite death; these mechanisms were elucidated alongside work by scientists affiliated with Imperial College London and Harvard Medical School. Its immunomodulatory effects are attributed to lysosomal pH elevation in host cells, modulation of Toll-like receptor signaling noted in research from National Institutes of Health laboratories, and interference with antigen presentation pathways investigated at universities including Johns Hopkins University.

Pharmacology

Chloroquine is well absorbed after oral administration with variable bioavailability documented in pharmacokinetic studies reported by academic centers such as University of Oxford and Karolinska Institutet. It undergoes extensive hepatic metabolism partly via cytochrome P450 isoenzymes characterized in work from University of Cambridge, and exhibits a large volume of distribution due to tissue sequestration, notably in retinal and cardiac tissues described in toxicology reports from Mayo Clinic and Massachusetts General Hospital. The drug’s terminal half-life is prolonged, producing interactions with agents listed by agencies such as the Food and Drug Administration and metabolism studies involving collaborations with Novartis and academic pharmacology departments.

Adverse effects and toxicity

Dose- and duration-related adverse effects include retinopathy linked to cumulative exposure monitored by specialty clinics such as Bascom Palmer Eye Institute and electrophysiologic abnormalities reported in case series from Cleveland Clinic. Cardiotoxicity including conduction disturbances and cardiomyopathy has been described in case reports reviewed by cardiology divisions at Johns Hopkins Hospital and Stanford Hospital. Other toxicities—hypoglycemia, neuropsychiatric manifestations, and dermatologic reactions—were catalogued in pharmacovigilance databases managed by agencies like the European Medicines Agency and the Pharmaceutical Benefits Advisory Committee in various jurisdictions.

Resistance and epidemiology

Widespread resistance of Plasmodium falciparum to chloroquine emerged in the mid-20th century with key epidemiologic reports from regions including Southeast Asia, Sub-Saharan Africa, and South America; surveillance efforts have been coordinated by World Health Organization and regional bodies such as the African Union. Molecular mechanisms of resistance involve mutations in parasite transport proteins identified in research groups at Wellcome Sanger Institute and Institut Pasteur de Madagascar, which shifted treatment policies to artemisinin-based combination therapies recommended by World Health Organization guidelines. Resistant parasite lineages and their global dissemination were tracked using genomic epidemiology collaborations including projects led by MalariaGEN.

History and society

Chloroquine development and deployment trace back to synthetic antimalarial research in the 1930s and 1940s with industrial contributions from firms such as Bayer and academic chemists at University of Pennsylvania. Its role in postwar eradication campaigns implicated public health programs run by World Health Organization and national ministries, influencing geopolitical health initiatives during the Cold War. Social debates over drug access, patenting, and repurposing entered public discourse with involvement from advocacy groups like Médecins Sans Frontières and policy makers in bodies such as the United Nations. High-profile media coverage and political statements during emergent health crises brought chloroquine into prominence in newsrooms of outlets including The New York Times and BBC News.

Research and experimental use

Research into chloroquine has spanned antiviral screening in laboratories affiliated with National Institutes of Health and experimental oncology trials at institutions like Memorial Sloan Kettering Cancer Center, exploring autophagy inhibition and chemosensitization. Investigations into activity against emerging pathogens prompted preclinical studies at Centers for Disease Control and Prevention and consortium trials coordinated with universities including University of Oxford and University of Melbourne. Regulatory agencies such as the European Medicines Agency and U.S. Food and Drug Administration have overseen clinical trial approvals and issued guidance as evidence from randomized controlled trials and meta-analyses produced by collaborative networks like the Cochrane Collaboration.

Category:Antimalarial agents